Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

SML3513

Sigma-Aldrich

Lorcaserin hydrochloride

≥98% (HPLC)

Synonym(e):

(1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride, (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride, (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride, APD 356 hydrochloride, APD-356 hydrochloride, APD356 hydrochloride

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C11H14ClN·HCl
CAS-Nummer:
846589-98-8
Molekulargewicht:
232.15
MDL-Nummer:
MFCD09833667
UNSPSC-Code:
12352200
NACRES:
NA.04

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

powder

Arzneimittelkontrolle

USDEA Schedule IV

Lagerbedingungen

desiccated

Farbe

white to beige

Löslichkeit

H2O: 2 mg/mL, clear

Lagertemp.

-10 to -25°C

Biochem./physiol. Wirkung

Lorcaserin is an orally active, potent and selective 5-hydroxytryptamine receptor (5-HT2C) agonist (human/rat Ki = 15 /29 nM) with 18- and 104-fold higher potency than 5-HT2A and 5-HT2B by cellular inositol phosphate accumulation assay (EC50 = 9, 168, 943 nM, respectively) and good selectivity over 5-HT1A/3/4C/5A/6/7 and a panel of 67 other GPCRs and ion channels. Chronic daily treatment to rats (4.5-18 mg/kg p.o. b.i.d.) maintained on a high fat diet causes reductions in food intake and body weight gain.

Vorsicht

Hygroscopic

Piktogramme

Health hazardExclamation mark
GHS08,GHS07

Signalwort

Warning

H-Sätze

H302,H351

Gefahreneinstufungen

Acute Tox. 4 Oral - Carc. 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Lisa R Gerak et al.
Drug and alcohol dependence, 227, 108991-108991 (2021-09-06)
The opioid epidemic continues despite the availability of medications, including buprenorphine, for opioid use disorder (OUD); identifying novel and effective treatments is critical for decreasing the prevalence of OUD and ending this crisis. Buprenorphine alone does not markedly attenuate abuse-related
Yang He et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 41(26), 5734-5746 (2021-05-26)
Obesity is a serious global health problem because of its increasing prevalence and comorbidities, but its treatments are limited. The serotonin 2C receptor (5-HT2CR), a G-protein-coupled receptor, activates proopiomelanocortin (POMC) neurons in the arcuate nucleus of hypothalamus (ARH) to reduce
William J Thomsen et al.
The Journal of pharmacology and experimental therapeutics, 325(2), 577-587 (2008-02-07)
5-Hydroxytryptamine (5-HT)(2C) receptor agonists hold promise for the treatment of obesity. In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT(2C) full agonist. Lorcaserin bound to human and rat
Muhan Jing et al.
Frontiers in pharmacology, 12, 761966-761966 (2021-11-23)
Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity. Lorcaserin can restrain patients' appetite and improve insulin sensitivity and

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.